Named on one round in the feed.
Since 2026-09-24
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Kasvu Therapeutics A company developing a new generation of neuroplastogens for neuropsychiatric and neurodegenerative disorders | Series A Verified against 6 sources | $34.1M | 2026-09-24 | [ PART ] |